Qihui Huang

TL;DR: It is demonstrated that Fc receptor binding augmented the production of proinflammatory cytokines in a two-way mixed leukocyte reaction using a fully human anti-CD73, and this co-blockade limits tumor initiation, growth, and metastasis.

TL;DR: It is shown that MEDI9447 is a potent inhibitor of CD73 ectonucleotidase activity, with wide ranging immune regulatory consequences, that results in relief from adenosine monophosphate (AMP)-mediated lymphocyte suppression in vitro and inhibition of mouse syngeneic tumor growth in vivo.

TL;DR: Phenotypic profiling using complex 3-D cell cultures steers hit selection towards more relevant in vivo phenotypes, and may shed light on subtle mechanistic variations in drug candidates, enabling data-driven decisions for oncology target validation.

TL;DR: Data showing additive activity between MEDI9447 and other immune-mediated therapy antibodies demonstrates the importance of relieving adenosine-mediated immunosuppression within tumors.

TL;DR: Level and enzyme activity of CD73 in primary samples from cancer patients and a potential role of surface and sCD73 as a pharmacodynamic and/ or predictive biomarker of anti-CD73 immunotherapy are suggested.